I expect today's PR concerning the completion of the Prurisol P2B trial with expected top line results in Q1 2018 to be the last PR for this year (at least I hope it is). Any further PR's, such as Kevetrin update, would be better served being released in early Jan 2018 IMO as anything now will get lost in the Holiday shuffle.
Happy to see progression exactly as planned and believe results will be in line with our high expectations. Can't expect more from the company as all three drugs should get significant updates in Q1. 2018 shaping up to be a gangbuster!!
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links